FERRATUM OYJ Original-Research: Multitude SE (von NuWays AG): BUY
Transparency directive : regulatory news
Original-Research: Multitude SE - from NuWays AG
Classification of NuWays AG to Multitude SE
Company Name: Multitude SE
ISIN: FI4000106299
Reason for the research: Update
Recommendation: BUY
from: 06.03.2024
Target price: 10.00
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Frederik Jarchow
Small value-accretive acquisition through CapitalBox; chg
Yesterday, Multitude announced to have acquired the Danish factoring specialist Omniveta Finance through its SME unit CapitalBox. Last week, CapitalBox also launched a new collateral lending product. In detail:
Value-accretive acquisition. Founded in 2012, Omniveta is a factoring
specialist, that is purchasing invoices (eNuW: on avg. 30 days credit
period) from suppliers with a certain discount (eNuW: 10-20%, including
handling fees). With that, Omniveta is improving the overall liquidity of
Danish SME´s. We expect that the company is generating a low single digit
million Euro amount in sales and being more or less break-even on the
bottom line. Multitude is seen to have paid
You can download the research here:
http://www.more-ir.de/d/29079.pdf
For additional information visit our website
www.nuways-ag.com/research.
Contact for questions
Die Analyse oder weiterführende Informationen zu dieser können Sie hier downloaden
www.nuways-ag.com/research.
Kontakt für Rückfragen
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
-------------------transmitted by EQS Group AG.-------------------
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.